In early drug discovery, the transition from target identification to validated hit and lead series remains a critical bottleneck – particularly for complex targets such as under-characterized transmembrane receptors implicated in inflammation, fibrosis, and cancer. Fragmented outsourcing models and limited translational feedback between chemistry and biology teams often slow progress, inflate costs, and increase churn rates.
Ascentia addresses this gap by integrating medicinal and synthetic chemistry with biological target validation and assay development within one coordinated CRO ecosystem. Our mission is to accelerate discovery of small-molecule therapeutics by combining scientific depth, modern infrastructure, and collaborative partnerships with academia and biotech innovators.
We are currently expanding joint R&D efforts to explore novel modulators of GPCRs and other challenging transmembrane proteins, including first-in-class molecular probes and chemical tools that enable deeper mechanistic understanding.